Adam Waxman, MD, MS
Hematology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 4th Floor West
Penn Medicine Provider

About me

  • Assistant Professor of Clinical Medicine (Hematology-Oncology)

Education and training

  • Residency: University of Pennsylvania Health System
  • Fellowship: University of Pennsylvania Health System

What my patients think about me

Average Rating

1299 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
April 2026
dr waxman is very professional and very thorough. he is not rushed and explains everything . he provides time to ask any questions i may have.
Anonymous
April 2026
great visit. great dialog and discussion.
Anonymous
April 2026
my physician has expert knowledge, kind, professional and answers all of my questions while giving me the latest information available.
Anonymous
April 2026
i am a myeloma patient. he is a myeloma expert. any patient with myeloma should have a myeloma expert as part of their treatment team.

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Waxman is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Ho M, Paruzzo L, Noll JH, Stella F, Devi P, Ndeupen S, Day YA, Chen GM, Cohen IJ, Ramirez-Fernandez A, Waxman AJ, Kapur S, Chen F, Xu R, Huff A, Jarocha D, Patel V, Bochi-Layec AC, Ramasubramanian R, Liu S, Bouvier R, de Souza VB, Patel H, Li Z, Carturan A, Michener P, Hopkins CR, Koucky O, Minehart J, Dimitri A, Nabar NR, Hasanali ZS, Ciccarelli BT, Hung P, Williams E, Bartoszek R, Lavorando M, Mohan S, Gonzalez VE, Porazzi P, Bhoj VG, Apostolidis SA, Vogl DT, Porter DL, Scholler J, Diorio C, Roche AM, Everett JK, Bushman FD, Nathanson KL, Stadtmauer EA, Susanibar-Adaniya SP, Garfall AL, Ruella M, Cohen AD, Fraietta JA CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy. , Nature Medicine, 32(2): 2026,702-716.


Patel H, Hubbeling H, Yu K, Carpenter M, LaRiviere MJ, Plastaras JP, Cohen AD, Kapur S, Vogl DT, Waxman AJ, Stadtmauer EA, Garfall AL, Susanibar-Adaniya S. Outcomes of radiation integrated with T-cell-engaging bispecific antibodies in relapsed/refractory multiple myeloma , Blood Advances, 10(4): 2025,1395-1399


Yu KL, Ho M, Paruzzo L, Stella F, Patel H, Hasanali ZS, Kapur S, Waxman AJ, Vogl DT, Stadtmauer EA, Fraietta JA, Ruella M, Cohen AD, Garfall AL, Susanibar-Adaniya S. Outcomes of relapse after teclistamab therapy in multiple myeloma. , Blood Cancer Journal, 15(1): 2025,193


Yu K, Ho M, Paruzzo L, Stella F, Patel H, Hasanali Z, Kapur S, Waxman AJ, Vogl DT, Stadtmauer EA, Fraietta JA, Ruella M, Cohen AD, Garfall AL, Susanibar-Adaniya S. Outcomes of relapse after teclistamab therapy in multiple myeloma. , Blood Cancer J, 15(1): 2025


Kyle L. Yu, Matthew Ho, Luca Paruzzo, Federico Stella, Heta Patel, Zainul S. Hasanali, Shivani Kapur, Adam J. Waxman, Dan T. Vogl, Edward A. Stadtmauer, Joseph A. Fraietta, Marco Ruella, Adam D. Cohen, Alfred L. Garfall & Sandra Susanibar-Adaniya Outcomes of relapse after teclistamab therapy in multiple myeloma , Blood cancer journal, 15(1): 2025


Ho M, Paruzzo L, Minehart J, Voruganti T, Devi P, Vogl DT, Cohen AD, Garfall AL, Waxman AJ, Kapur S, Stadtmauer EA, Adaniya SS, Longworth S. Non-tuberculous mycobacterial infections following teclistamab in multiple myeloma. , Haematologica, 110(6): 2025,1436-1442


Stalker M, Garfall A, Cohen A, Vogl DT, Djulbegovic M, Susanibar-Adaniya S, Stadtmauer E, Megherea O, Waxman AJ. Safety and Efficacy of Teclistamab in Patients With Relapsed or Refractory AL Amyloidosis. , European Journal of Haematology, 114(3): 2025,443-447.


Elghawy O, Deshpande S, Sussman J, Garfall A, Cohen A, Kapur S, Susanibar-Adaniya S, Vogl D, Waxman A, Stadtmauer E. Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma , Bone Marrow Transplant, 60(1): 2025,64-68


Elghawy O, Deshpande S, Sussman J, Garfall A, Cohen A, Kapur S, Susanibar-Adaniya S, Vogl D, Waxman A, Stadtmauer E. Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma. , Bone Marrow Transplant, 60(1): 2025,64-68


Stalker M, Garfall A, Cohen A, Vogl DT, Djulbegovic M, Susanibar-Adaniya S, Stadtmauer E, Megherea O, Waxman AJ Safety and Efficacy of teclistamab in Patients with Relapsed or Refractory AL Amyloidosis , European Journal of Haematology, 114(3): 2024,443-447


View all publications